HCT-116-luc Orthotopic Mouse Model Service for Colon Cancer

The HCT-116-luc orthotopic mouse model pairs the microsatellite instability-high (MSI-high) molecular profile and pronounced metastatic capacity of the parental HCT-116 human colorectal carcinoma with firefly luciferase reporter technology, enabling longitudinal, non-invasive visualization of primary tumor growth and spontaneous distant dissemination within an immunodeficient host. Alfa Cytology engineers this orthotopic xenograft platform with authenticated luciferase-expressing human cell stocks, standardized cecal wall implantation in athymic hosts, and integrated IVIS bioluminescence imaging infrastructure, delivering quantitative in vivo datasets that capture tumor invasion kinetics, treatment-induced regression, and metastatic colonization patterns with temporal resolution essential for evaluating immunotherapy, targeted agents, and combination strategies in MSI-high colorectal malignancies.

Overview of HCT-116-luc Orthotopic Mouse Model for Colon Cancer

The HCT-116 cell line is a human colorectal adenocarcinoma originally isolated in 1979 from epithelial tumor tissue of the ascending colon of an adult male patient. Genetically, HCT-116 is classified within the microsatellite instability-high (MSI-high) molecular subtype, driven by deficient mismatch repair (dMMR) arising from pathogenic mutations in MLH1 (p.S252Ter stop-gain) and MSH6 (p.F1088LfsTer5 frameshift). The line harbors a heterozygous KRAS activating mutation (G13D, p.Gly13Asp) and a heterozygous PIK3CA hotspot mutation (H1047R, p.His1047Arg), alongside an inframe deletion in CTNNB1 (p.S45del) and a frameshift mutation in BRCA2—collectively rendering it a representative model for the MSI-high, KRAS-driven, WNT-activated subset of colorectal carcinoma that exhibits exceptional sensitivity to immune checkpoint blockade. The luciferase-transduced derivative (HCT-116-luc) was generated by stable integration of firefly (Photinus pyralis) luciferase under constitutive promoter control, with puromycin selection ensuring sustained reporter expression. This optical reporting capability enables quantitative tracking of tumor burden and metastatic spread through D-luciferin substrate administration and IVIS spectrum detection.

Fig 1. Workflow for establishing an HCT116-Luc orthotopic colorectal cancer model, from luciferase-labeled cell preparation and xenograft generation to orthotopic transplantation and bioluminescence-based assessment of hepatic metastasis. (Zhang, Yajuan, et al., 2023)

Orthotopic implantation of HCT-116-luc cells into the cecal wall of immunodeficient mice (athymic nude or NOD-scid strains) reconstructs the anatomical positioning, stromal architecture, and lymphatic drainage of clinical colorectal cancer. Tumors establish reliably within 7–10 days post-implantation, with bioluminescence signals detectable shortly thereafter. A defining characteristic of this model is its pronounced metastatic potential: documented rates of 68% for liver and/or lung metastasis following orthotopic engraftment, attributed to upregulated survival and migratory signaling pathways and a low apoptotic index under stress. The moderate-to-rapid growth kinetics (reaching 1,500–2,000 mm³ over 4–6 weeks) provide a practical therapeutic window for evaluating both locoregional control and systemic anti-metastatic strategies. The combination of MSI-high tumor biology, documented metastatic behavior, and bioluminescence tracking renders this model exceptionally powerful for preclinical evaluation of PD-1/PD-L1 inhibitors, MEK inhibitors, PI3K pathway antagonists, and novel agents targeting the metastatic cascade.

Cell Line Information: HCT-116-luc

The HCT-116-luc cell line merges the genetically well-defined, MSI-high colorectal carcinoma phenotype of the parental HCT-116 line with a stably integrated firefly luciferase reporter cassette, enabling quantitative optical readouts of tumor burden and metastatic dissemination. The table below consolidates its essential biological, genetic, reporter, and culture parameters:

Our Services

Alfa Cytology delivers a comprehensive HCT-116-luc orthotopic model service spanning authenticated luciferase-expressing human cell line banking, surgical cecal wall implantation in immunodeficient hosts, serial bioluminescence imaging, therapeutic intervention, metastasis surveillance, and multi-parameter endpoint analysis. Our platform is optimized for MSI-high colorectal cancer studies, leveraging real-time optical tracking and documented metastatic behavior to generate mechanistically rich, temporally resolved datasets that inform your drug development strategy from primary tumor control through distant dissemination.

Workflow of HCT-116-luc Orthotopic Mouse Model Construction

Establishment of the HCT-116-luc orthotopic model requires coordinated execution of luciferase validation, sterile surgical technique, and calibrated bioluminescence imaging to achieve consistent engraftment and meaningful optical signal kinetics in an immunodeficient host. The protocol proceeds through the following sequential stages:

1. Cell Expansion and Luciferase Validation: HCT-116-luc cells are propagated under puromycin selection to maintain luciferase expression, authenticated via STR profiling against the human reference, and confirmed mycoplasma-negative. Luciferase activity is quantified in vitro using a D-luciferin luminometric assay to verify reporter functionality and establish baseline photon flux per cell prior to in vivo use. Cells are harvested during logarithmic growth, counted, and resuspended in ice-cold PBS.
2. Recipient Mouse Preparation: Female athymic nude (BALB/c nu/nu) or NOD-scid mice (6–8 weeks old) are quarantined and acclimated for a minimum of 72 hours. Health status is assessed daily, and any mice displaying abnormal behavior or weight loss are excluded prior to cell implantation.
3. Matrigel Suspension Preparation: The cell suspension is mixed 1:1 by volume with ice-cold Matrigel Basement Membrane Matrix immediately prior to injection. Matrigel provides an extracellular scaffold that supports initial tumor colonization within the cecal wall, enhances engraftment consistency, and facilitates stromal interaction.
4. Surgical Cecal Wall Implantation: Under general anesthesia, a midline laparotomy (~10 mm) is performed, and the cecum is exteriorized onto sterile gauze moistened with PBS. A small cecotomy is made at the cecal tip, and 50–100 µL of the Matrigel-cell suspension (1 × 10⁶ cells) is injected submucosally into the cecal wall from the luminal side using a 27-gauge needle. The cecotomy is closed with interrupted 5-0 silk sutures, the cecum is returned to the abdominal cavity, and the abdominal wall is closed in two layers.
5. Postoperative Care and Monitoring: Mice receive sustained-release buprenorphine for analgesia and are monitored closely during the 48-hour perioperative period. Body weights are recorded daily for the first week and twice weekly thereafter to detect early cachexia or treatment-related toxicity.
6. Baseline Bioluminescence Imaging and Cohort Stratification: At 7–10 days post-implantation, mice receive intraperitoneal D-luciferin (150 mg/kg) and are imaged under isoflurane anesthesia using an IVIS spectrum system. Tumor-bearing mice with detectable bioluminescent signals are stratified by photon flux intensity into homogeneous treatment cohorts, ensuring balanced baseline signal distributions across all experimental arms.
7. Therapeutic Intervention and Serial Bioluminescence Monitoring: Test compounds are administered according to the predefined regimen. Bioluminescence imaging is performed at regular intervals (typically weekly) to quantify primary tumor growth dynamics, treatment-induced signal attenuation, and potential metastatic dissemination to distant organs. Photon flux values are normalized to baseline and plotted over time. Body weights and clinical signs are recorded concurrently.
8. Endpoint Necropsy, Ex Vivo Imaging, and Comprehensive Analysis: Upon reaching study endpoints (tumor volume ~2,000 mm³, humane moribund criteria, or scheduled termination), mice are euthanized. The primary cecal tumor is excised, weighed, and photographed. Ex vivo bioluminescence imaging of excised tumors and organs (liver, lungs, mesenteric lymph nodes) is performed to confirm metastatic dissemination. Tissues are fixed for H&E and immunohistochemistry (CD31, Ki-67, cleaved caspase-3, phospho-ERK, phospho-AKT, PD-L1), or snap-frozen for Western blot, qPCR, and RNA-seq.

Fig 2. HCT-116-luc Orthotopic Mouse Model construction workflow.

Case Study-HCT-116-luc Orthotopic Mouse Model Development

In a preclinical program investigating immune checkpoint blockade efficacy in MSI-high colorectal cancer, the HCT-116-luc orthotopic model was employed to evaluate the antitumor activity of a novel anti-PD-1 antibody administered as monotherapy and in combination with a MEK inhibitor. Following surgical cecal wall implantation and baseline bioluminescence imaging stratification, treatment cohorts received the anti-PD-1 antibody alone, the MEK inhibitor alone, the combination regimen, or vehicle control. Serial bioluminescence imaging revealed rapid and sustained signal attenuation in the combination cohort, with several mice achieving near-complete photon flux loss indicative of profound tumor regression, whereas the anti-PD-1 monotherapy group exhibited moderate initial response followed by gradual signal stabilization. The MEK inhibitor monotherapy showed minimal effect on primary tumor signal intensity. Endpoint necropsy and ex vivo imaging confirmed reduced metastatic burden in the liver and lungs of the combination-treated group compared to vehicle controls. Histopathological analysis demonstrated increased CD8⁺ T-cell infiltration and elevated PD-L1 expression in the combination-treated primary tumors, alongside reduced Ki-67 proliferation indices and enhanced cleaved caspase-3 staining. These findings illustrate the model's capacity to capture both primary tumor response and anti-metastatic effects through longitudinal optical tracking, providing actionable insights for optimizing immunotherapy-based combination strategies in MSI-high colorectal malignancies.

Why Choose Alfa Cytology?

Partnering with Alfa Cytology for your HCT-116-luc orthotopic colon cancer study provides access to a specialized platform that bridges MSI-high human tumor biology with quantitative bioluminescence imaging and metastasis assessment. Our distinguishing capabilities include:

• Authenticated HCT-116-luc cell banking with documented STR profiling, mycoplasma clearance, and passage-controlled expansion to preserve MSI-high genetic identity, KRAS/PIK3CA mutation fidelity, and luciferase reporter integrity across cohorts.
• In-house IVIS bioluminescence imaging infrastructure enabling quantitative, non-invasive tracking of primary tumor growth and spontaneous metastatic dissemination with normalized photon flux analysis and ex vivo confirmation.
• Skilled surgical team experienced in cecal wall orthotopic implantation with robust engraftment rates and low perioperative mortality, ensuring adequate statistical power for both primary tumor and metastasis endpoint analysis.
• Integrated histopathology and molecular profiling capabilities featuring validated antibody panels for PD-L1, CD8, phospho-ERK, phospho-AKT, Ki-67, cleaved caspase-3, and CD31 vascular markers, alongside MSI status verification.
• Flexible combination study designs supporting immune checkpoint inhibitors, MEK inhibitors, PI3K inhibitors, and anti-metastatic agents with customized dosing schedules, sequential treatment arms, and pharmacodynamic sampling timepoints.
• Dedicated project scientists providing weekly bioluminescence data updates, interim metastasis assessments, and collaborative interpretation of temporal response trends to align preclinical outcomes with your clinical development strategy for MSI-high colorectal cancer.

Contact Us

If your preclinical program requires an MSI-high colorectal cancer model with documented metastatic potential and the power of real-time bioluminescence tracking, we invite you to reach out to us to explore how Alfa Cytology can design and execute a tailored HCT-116-luc orthotopic study aligned with your therapeutic objectives. From surgical implantation and serial imaging through metastasis surveillance and comprehensive endpoint profiling, our scientific team is committed to delivering quantitative, mechanism-informed insights that de-risk your colorectal cancer drug development decisions. Contact us today to initiate your project and leverage our integrated bioluminescence imaging platform for your next-generation MSI-high therapeutic candidate.

For research use only. Not intended for any clinical use.